Eli Lilly (LLY) is down 1.67% as the company announced a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics on Wednesday.
The deal centers on developing kidney-disease treatments using Ascidian’s RNA-exon-editing technology. Lilly has been granted exclusive, target-specific rights to the technology for undisclosed kidney-disease targets.
RNA-exon editors work by altering parts of genetic code to repair faulty genetic instructions that cause disease. Ascidian says its editors are specifically designed to edit nucleotide sequences known as exons, which it says reduces the risks linked to DNA editing and gene replacement therapies.
Eli Lilly struck a deal worth up to $1.9 billion with privately held biotech Ascidian Therapeutics to develop treatments for rare kidney diseases, expanding the obesity drugmaker’s push into genetic medicines. https://t.co/R1W5WAsu7e
— Bloomberg (@business) June 3, 2026
Under the terms of the agreement, Ascidian will lead discovery and certain preclinical activities. Lilly then takes over for additional preclinical work, clinical development, manufacturing, and commercialization.
Ascidian is eligible to receive up to $1.9 billion in total. That includes an upfront payment, development and commercial milestone payments, and tiered royalties on commercial sales worldwide.
Ascidian is retaining the right to pursue other kidney-disease targets independently outside of this deal.
Lilly is responsible for the later-stage work — taking Ascidian’s early-stage discoveries through clinical trials and eventually to market. That’s a significant division of labor, letting Ascidian focus on what it does best while Lilly handles the heavy lifting of getting a drug approved and sold.
The Indiana-based drugmaker has been on a dealmaking run recently, using cash generated from its blockbuster GLP-1 weight-loss drugs to fund new partnerships. This kidney-disease deal is the latest move in that strategy.
Ascidian is a Boston-based biotech. Its RNA-exon-editing platform is designed to correct genetic errors at the RNA level rather than modifying DNA directly.
That distinction matters. Editing RNA is considered a lower-risk approach compared to permanent DNA changes or gene replacement therapies.
The specific kidney-disease targets covered by the deal have not been disclosed by either company.
Ascidian confirmed it retains rights to other kidney-disease targets not covered by this collaboration, leaving the door open for future independent or partnered programs.
The deal was announced on Wednesday, June 3, 2026.
The post Eli Lilly (LLY) Stock Signs $1.9B Kidney Disease Deal With Ascidian Therapeutics appeared first on CoinCentral.
